Literature DB >> 10135639

The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer.

A D'Amico1, M Altschuler, R Whittington, G Kao, S B Malkowicz, A Wein.   

Abstract

The capability of an interactive statistical package (ISP) to predict the patients whose pathologic findings at the time of radical prostatectomy for prostate cancer would require postoperative radiation therapy to prevent local failure is investigated. A retrospective review of the clinical pretreatment factors and pathologic findings of 174 patients with adenocarcinoma of the prostate treated from 1989 to 1993 with radical retropubic prostatectomy was performed and served as a knowledge base of the ISP. The pathologic findings of seminal vesicle involvement, gross transcapsular disease, and positive surgical margins are defined as outcomes associated with a high risk of local failure after radical prostatectomy and, thereby, requiring postoperative radiation therapy to decrease this risk. By using the pretreatment clinical factors including prostate-specific antigen (PSA), Gleason score, clinical stage, and endorectal magnetic resonance imaging (MRI) findings as input to the ISP, patients are identified from a test group of 50 cases with known pathologic outcome who would require postoperative radiotherapy to decrease local failure. Low- (0% to 33%), intermediate- (34% to 67%), and high-risk groups (68% to 100%) for pathologic features associated with local failure were predicted accurately (r > .95) by the ISP for the 50 test cases. Factors identified on univariate analysis by the ISP as significant predictors of local failure postoperatively include PSA > 20 (p < .001), clinical stage (p < .001), MRI finding of gross transcapsular disease (p < .001), MRI finding of seminal vesicle involvement (p < .001), and Gleason score (p < .003).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 10135639

Source DB:  PubMed          Journal:  Clin Perform Qual Health Care        ISSN: 1063-0279


  6 in total

1.  [Radiation therapy for prostate cancer in the new S3 guideline. Part 1: localized and locally advanced prostate cancer].

Authors:  D Böhmer; F Wenz; T Martin; F Sedlmayr; W Hinkelbein; T Wiegel
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

2.  The German S3 guideline prostate cancer: aspects for the radiation oncologist.

Authors:  Frederik Wenz; Thomas Martin; Dirk Böhmer; Stefan Martens; Felix Sedlmayer; Manfred Wirth; Kurt Miller; Axel Heidenreich; Mark Schrader; Wolfgang Hinkelbein; Thomas Wiegel
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

3.  [Treatment mapping of prostate cancer in DVPZ prostate centers in Germany].

Authors:  R Berges; T Ebert; W Schafhauser; W Schultze-Seemann; M Braun; J Herden; P Weib; M Garcia Schürmann; M Reimann; C Bornhof; F Oberpenning; P Baur; J Zumbé; E Gronau; W Diederichs; O A Brinkman; M Goepel; A Göll; K Hoefner; M Kriegmair; S Laabs; B Planz; G Platz; A Heidenreich
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

4.  Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre.

Authors:  Anna Boladeras; Evelyn Martinez; Ferran Ferrer; Cristina Gutierrez; Salvador Villa; Joan Pera; Ferran Guedea
Journal:  Rep Pract Oncol Radiother       Date:  2016-02-20

5.  Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study.

Authors:  Evelyn Martínez; Olatz Garin; Yolanda Pardo; Pablo Fernández; Benjamin Guix; Cristina Gutiérrez; Ana Boladeras; Ferran Ferrer; Tania Hernández; Adriana Ayala; Mikel Egiguren; Gema Fernández; Víctor Muñoz; Víctor Macías; Joan Pera; Àngels Pont; Montserrat Ferrer; Ferran Guedea
Journal:  J Contemp Brachytherapy       Date:  2021-02-18

Review 6.  The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy.

Authors:  Nigel P Murray; Socrates Aedo; Cynthia Fuentealba; Eduardo Reyes; Simone Minzer; Aníbal Salazar
Journal:  Ecancermedicalscience       Date:  2018-06-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.